Ikan is involved in tackling the threat of antimicrobial resistance. Antimicrobial resistance is one of the major global health threats today. Existing antimicrobials, such as antibiotics, are becoming less effective as antimicrobial resistant organisms are outpacing the development of new drugs.
At Ikan we are helping our customers to tackle multiresitant bacteria by developing novel, innovative and efficient natural solutions; one example is the development of Enzybiotics (Endolysins) against both Gram Positive or Gram Negative mutiresistant bacteria.
In the development of new antimicrobial agents, it is necessary to switch to whole organism studies using animal models after in silico and in vitro studies have been carried out. At Ikan we are the only ones to carry out such trials with zebrafish and allow for complete in house development from in silico to in vivo studies.